BiotechTube

Trontinemab

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimers Disease

Conditions

Alzheimers Disease

Trial Timeline

Nov 12, 2025 → Jun 7, 2028

NCT ID
NCT07170150

About Trontinemab

Trontinemab is a phase 3 stage product being developed by Roche for Alzheimers Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07170150. Target conditions include Alzheimers Disease.

What happened to similar drugs?

0 of 4 similar drugs in Alzheimers Disease were approved

Approved (0) Terminated (1) Active (3)
🔄TrontinemabRochePhase 3
❌Gantenerumab + PlaceboRochePhase 3
🔄Semaglutide + PlaceboNovo NordiskPhase 3
🔄buntanetap/posiphen + PlaceboAnnovis BioPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07170150Phase 3Recruiting
NCT07169578Phase 3Recruiting

Competing Products

15 competing products in Alzheimers Disease

See all competitors
ProductCompanyStageHype Score
E2814 + Lecanemab + Matching Placebo (E2814)EisaiPhase 2/3
42
Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814)EisaiPhase 2/3
42
Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab)Eli LillyPhase 2/3
38
Remternetug + Matching Placebo (Remternetug)Eli LillyPhase 2/3
45
Remternetug (SC) + Matching Placebo (Remternetug)Eli LillyPhase 2/3
45
CNP520 50mg + CNP520 15mgNovartisPhase 2/3
30
CAD106 Immunotherapy + CNP520NovartisPhase 2/3
30
RO7126209 + PlaceboRochePhase 1
29
RO7126209 + PlaceboRochePhase 1/2
36
GantenerumabRochePhase 2/3
30
TrontinemabRochePhase 3
47
Gantenerumab + PlaceboRochePhase 3
32
Semaglutide + PlaceboNovo NordiskPhase 3
40
X/T + X-EC + Placebo + Lecanemab 10 mg/kgBristol Myers SquibbPhase 2
42
buntanetap/posiphen + PlaceboAnnovis BioPhase 3
37